Clinical Trial Update: Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of Imatinib Mesylate in patients with Stage IV colorectal cancer (recurrent colon or rectal cancer) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Status: COMPLETED